Godfrey Phillips India Enters 3-Year Distribution Agreement with Aspeya India for Nicotine Replacement Therapy Products

2 min read     Updated on 15 May 2026, 11:12 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Godfrey Phillips India Limited approved a Distribution Agreement with Aspeya India Private Limited on 15th May 2026 for the distribution and re-sale of Nicotine Replacement Therapy products through domestic approved channels of trade. The initial term of the agreement is three years, subject to customary warranties and indemnities. Aspeya India, a related party entity linked to foreign promoter Philip Morris Global Brands Inc., USA, reported revenue from operations of Rs. 795.06 lakhs and profit after tax of Rs. 19.32 lakhs for the year ended 31st March 2025. The agreement is intended to leverage Godfrey Phillips India's distribution network to add to its top-line and bottom-line.

powered bylight_fuzz_icon
40412502

*this image is generated using AI for illustrative purposes only.

Godfrey Phillips India Limited has entered into a Distribution Agreement with Aspeya India Private Limited for the distribution and re-sale of Nicotine Replacement Therapy (NRT) products. The Board of Directors approved the agreement at its meeting held on 15th May 2026, which commenced at 2:45 PM and concluded at 4:00 PM. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agreement Structure and Scope

Under the terms of the agreement, Godfrey Phillips India will purchase NRT products marketed by Aspeya India and subsequently distribute or re-sell them through approved channels of trade within the agreed domestic territory. The company will utilise its existing distribution set-up to facilitate this arrangement. The agreement is domestic in nature and does not involve any share exchange ratio or upfront consideration.

The key terms of the distribution agreement are summarised below:

Parameter: Details
Agreement Type: Distribution Agreement
Products: Nicotine Replacement Therapy (NRT) Products
Territory: Domestic
Initial Term: 3 (three) years
Scope: Purchase and distribution/re-sale through approved channels of trade
Consideration: Not Applicable
Share Exchange Ratio: Not Applicable

Related Party Disclosure

Aspeya India Private Limited is a member entity of the group to which Philip Morris Global Brands Inc., USA — the foreign promoter shareholder of Godfrey Phillips India — belongs. Accordingly, the transactions under the agreement qualify as related party transactions. The company has disclosed that all transactions shall be undertaken in the ordinary course of business and at arm's length, with the nature of concern or interest being financial.

Aspeya India — Financial Profile

Aspeya India is engaged in the business of marketing pharmaceutical and nutraceutical products in India. Based on its last available audited financials for the year ended 31st March 2025, the financial highlights are as follows:

Metric: Amount
Revenue from Operations: Rs. 795.06 lakhs
Profit After Tax: Rs. 19.32 lakhs

Strategic Rationale

The agreement is expected to enable Godfrey Phillips India to leverage its established distribution infrastructure to distribute and re-sell Aspeya's NRT products. The company has indicated that this arrangement is anticipated to contribute positively to both its top-line and bottom-line performance. The agreement is subject to customary terms and conditions, including warranties and indemnities as set out in the agreement.

Historical Stock Returns for Godfrey Phillips

1 Day5 Days1 Month6 Months1 Year5 Years
+0.14%-5.83%+9.50%-19.84%-18.79%+670.87%

How might Godfrey Phillips India's entry into NRT distribution signal a broader strategic pivot toward reduced-risk or cessation products, and could this lead to similar agreements with other Philip Morris affiliates?

Given that Aspeya India reported only Rs. 795 lakhs in revenue for FY2025, what scale of distribution expansion would be needed for this agreement to materially impact Godfrey Phillips India's financials?

How could regulatory changes in India's NRT and pharmaceutical distribution landscape affect the viability and renewal of this three-year agreement beyond 2029?

Godfrey Phillips India's General Counsel Ms. Jaishree Tolani Resigns with Immediate Effect

1 min read     Updated on 15 May 2026, 07:24 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Godfrey Phillips India Limited disclosed the resignation of Ms. Jaishree Tolani, General Counsel and Senior Management Personnel, effective 14 May 2026 with immediate effect due to family reasons. The regulatory intimation was filed by Company Secretary Pumit Kumar Chellaramani under Regulation 30 of the SEBI Listing Regulations, along with the requisite annexures including her resignation letter.

powered bylight_fuzz_icon
40327115

*this image is generated using AI for illustrative purposes only.

Godfrey Phillips India Limited has informed the stock exchanges of the resignation of Ms. Jaishree Tolani, who served as General Counsel and Senior Management Personnel of the company. The resignation was tendered on 14 May 2026 and accepted with immediate effect. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Change

Ms. Tolani formally communicated her decision to step down from the role of General Counsel through a resignation letter addressed to the CEO of Godfrey Phillips India Limited. In her letter, she cited family reasons as the basis for her departure and requested to be relieved of her responsibilities effective the same day. The company duly accepted the resignation with immediate effect.

The following table outlines the key details of the senior management change as disclosed under Regulation 30 of the SEBI Listing Regulations:

Parameter: Details
Name: Ms. Jaishree Tolani
Designation: General Counsel
Reason for Change: Cessation due to resignation
Effective Date: Close of business hours on 14 May 2026
Reason Cited: Family reasons

Regulatory Disclosure

The intimation was filed by Pumit Kumar Chellaramani, Company Secretary and Compliance Officer of Godfrey Phillips India Limited, in accordance with the SEBI Master Circular dated 30 January 2026. The disclosure included the requisite details under Annexure-A along with a copy of Ms. Tolani's resignation letter as Annexure-B, as mandated under the applicable regulatory framework.

Historical Stock Returns for Godfrey Phillips

1 Day5 Days1 Month6 Months1 Year5 Years
+0.14%-5.83%+9.50%-19.84%-18.79%+670.87%

Who will Godfrey Phillips India appoint as the new General Counsel, and how might the transition affect ongoing legal and compliance matters?

Could the sudden departure of a key legal officer signal broader leadership instability at Godfrey Phillips India amid its ongoing corporate governance challenges?

How might the absence of a General Counsel impact Godfrey Phillips India's handling of any pending regulatory or litigation matters in the near term?

More News on Godfrey Phillips

1 Year Returns:-18.79%